Oncocytic versus mitochondrion-rich follicular thyroid tumours: Should we make a difference?

Histopathology

Volumn 55, Issue 6, 2009, Pages 665-682

  Tsybrovskyy, Oleksiy ^a   Rößmann Tsybrovskyy, Martina ^a  

^a RESEARCH INSTITUTE OF MOLECULAR PATHOLOGY   (Austria)

Author keywords

Endoplasmic; Immunohistochemistry; Mitochondrion; Neoplasm; Oncocytes; Prognosis; Reticulum; Thyroid

Indexed keywords

ADULT; ANTIBODY LABELING; ARTICLE; CANCER CELL; CANCER RECURRENCE; CELLULAR DISTRIBUTION; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; ENDOPLASMIC RETICULUM; FEMALE; FOLLICULAR CARCINOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MITOCHONDRION; PRIORITY JOURNAL; THYROID TUMOR;

ADENOCARCINOMA, FOLLICULAR; ADENOMA; CELL COUNT; DISEASE-FREE SURVIVAL; HUMANS; IMMUNOHISTOCHEMISTRY; MICROSCOPY, ELECTRON; MITOCHONDRIA; OXYPHIL CELLS; REGRESSION ANALYSIS; STATISTICS, NONPARAMETRIC; SURVIVAL ANALYSIS; THYROID GLAND; THYROID NEOPLASMS; TISSUE ARRAY ANALYSIS;

EID: 70849128470     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2009.03441.x     Document Type: Article

References (76)

1. Bocker W, Dralle H, Koch G, de Heer K, Hagemann J. Immunhistochemical and electron microscope analysis of adenomas of the thyroid gland. II. Adenomas with specific cytological differentiation. Virchows Arch. A Pathol. Anat. Histol. 1978 380 205 220.
2. Feldman PS, Horvath E, Kovacs K. Ultrastructure of three Hürthle cell tumors of the thyroid. Cancer 1972 30 1279 1285.
3. Nesland JM, Sobrinho-Simoes MA, Holm R, Sambade MC, Johannessen JV. Hürthle-cell lesions of the thyroid: a combined study using transmission electron microscopy, scanning electron microscopy, and immunocytochemistry. Ultrastruct. Pathol. 1985 8 269 290.
4. Sobrinho-Simoes MA, Nesland JM, Holm R, Sambade MC, Johannessen JV. Hürthle cell and mitochondrion-rich papillary carcinomas of the thyroid gland: an ultrastructural and immunocytochemical study. Ultrastruct. Pathol. 1985 8 131 142.
5. Asa SL. My approach to oncocytic tumours of the thyroid. J. Clin. Pathol. 2004 57 225 232.
6. LiVolsi VA. Surgical pathology of the thyroid. Philadelphia : W.B. Saunders Co., 1990 422.
7. Rosai J. Rosai and Ackerman's surgical pathology. Edinburgh : Mosby, 2004 544 547.
8. Rosai J, Kuhn E, Carcangiu ML. Pitfalls in thyroid tumour pathology. Histopathology 2006 49 107 120.
9. Rosai J, Carcangiu ML, DeLellis RA. Tumors of the thyroid gland, 3rd edn. Washington, DC : Armed Forces Institute of Pathology, 1992 343.
10. Chang A, Harawi SJ. Oncocytes, oncocytosis, and oncocytic tumors. Pathol. Annu. 1992 27 (Pt 1 263 304.
11. Tallini G. Oncocytic tumours. Virchows Arch. 1998 433 5 12.
12. Giorgadze T, Rossi ED, Fadda G, Gupta PK, Livolsi VA, Baloch Z. Does the fine-needle aspiration diagnosis of "Hürthle-cell neoplasm/follicular neoplasm with oncocytic features" denote increased risk of malignancy? Diagn. Cytopathol. 2004 31 307 312.
13. Bronner MP, LiVolsi VA. Oxyphilic (Askanazy/Hurthle cell) tumors of the thyroid: microscopic features predict biologic bevahiour. Surg. Pathol. 1988 1 137 150.
14. Gonzalez-Campora R, Herrero-Zapatero A, Lerma E, Sanchez F, Galera H. Hürthle cell and mitochondrion-rich cell tumors. A clinicopathologic study. Cancer 1986 57 1154 1163.
15. Carcangiu ML, Bianchi S, Savino D, Voynick IM, Rosai J. Follicular Hürthle cell tumors of the thyroid gland. Cancer 1991 68 1944 1953.
16. Haq M, Harmer C. Differentiated thyroid carcinoma with distant metastases at presentation: prognostic factors and outcome. Clin. Endocrinol. (Oxf) 2005 63 87 93.
17. Watson RG, Brennan MD, Goellner JR, van Heerden JA, McConahey WM, Taylor WF. Invasive Hürthle cell carcinoma of the thyroid: natural history and management. Mayo Clin. Proc. 1984 59 851 855.
18. Shaha AR, Loree TR, Shah JP. Prognostic factors and risk group analysis in follicular carcinoma of the thyroid. Surgery 1995 118 1131 1136. discussion 1136-1138.
19. Ozlem Kucuk N, Kulak H, Tokmak E, Tar P, Ibis E, Aras G. Hürthle cell carcinoma: a clinicopathological study of thirteen cases. Nucl. Med. Commun. 2006 27 377 379.
20. Evans HL, Vassilopoulou-Sellin R. Follicular and Hürthle cell carcinomas of the thyroid: a comparative study. Am. J. Surg. Pathol. 1998 22 1512 1520.
21. Ghossein RA, Hiltzik DH, Carlson DL et al. Prognostic factors of recurrence in encapsulated Hürthle cell carcinoma of the thyroid gland: a clinicopathologic study of 50 cases. Cancer 2006 106 1669 1676.
22. Sugino K, Ito K, Mimura T, Kameyama K, Iwasaki H. Hürthle cell tumor of the thyroid: analysis of 188 cases. World J. Surg. 2001 25 1160 1163.
23. Flint A, Lloyd RV. Hürthle-cell neoplasms of the thyroid gland. Pathol. Annu. 1990 25 (Pt 1 37 52.
24. Bhattacharyya N. Survival and prognosis in Hürthle cell carcinoma of the thyroid gland. Arch. Otolaryngol. Head Neck Surg. 2003 129 207 210.
25. Chao TC, Lin JD, Chen MF. Surgical treatment of Hürthle cell tumors of the thyroid. World J. Surg. 2005 29 164 168.
26. Haigh PI, Urbach DR. The treatment and prognosis of Hürthle cell follicular thyroid carcinoma compared with its non-Hürthle cell counterpart. Surgery 2005 138 1152 1157. discussion 1157-1158.
27. Paunovic I, Krgovic K, Tatic S et al. Surgery for thyroid Hürthle cell tumours - a single institution experience. Eur. J. Surg. Oncol. 2006 32 458 461.
28. Khafif A, Khafif RA, Attie JN. Hürthle cell carcinoma: a malignancy of low-grade potential. Head Neck 1999 21 506 511.
29. Besic N, Zgajnar J, Hocevar M, Frkovic-Grazio S. Is patient's age a prognostic factor for follicular thyroid carcinoma in the TNM classification system? Thyroid 2005 15 439 448.
30. Maximo V, Sobrinho-Simoes M. Hürthle cell tumours of the thyroid. A review with emphasis on mitochondrial abnormalities with clinical relevance. Virchows Arch. 2000 437 107 115.
31. Sobrinho-Simoes M, Maximo V, Castro IV et al. Hürthle (oncocytic) cell tumors of thyroid: etiopathogenesis, diagnosis and clinical significance. Int. J. Surg. Pathol. 2005 13 29 35.
32. Ljungberg O. Biopsy pathology of the thyroid and parathyroid. London : Chapman & Hall Medical, 1992 372.
33. Chan JKC. Tumours of the thyroid and parathyroid glands. In Fletcher CDM ed. Diagnostic histopathology of tumour. London : Churchill Livingstone, 2000 959 1038.
34. DeLellis RA ed. Pathology and genetics of tumours of endocrine organs. Lyon : IARC Press, 2004.
35. Tickoo SK, Amin MB, Linden MD, Lee MW, Zarbo RJ. Antimitochondrial antibody (113-1) in the differential diagnosis of granular renal cell tumors. Am. J. Surg. Pathol. 1997 21 922 930.
36. Chu PG, Weiss LM. Cytokeratin 14 immunoreactivity distinguishes oncocytic tumour from its renal mimics: an immunohistochemical study of 63 cases. Histopathology 2001 39 455 462.
37. Lazzi S, Spina D, Als C et al. Oncocytic (Hürthle cell) tumors of the thyroid: distinct growth patterns compared with clinicopathological features. Thyroid 1999 9 97 103.
38. Papotti M, Gugliotta P, Forte G, Bussolati G. Immunocytochemical identification of oxyphilic mitochondrion-rich cells. Appl. Immunohistochem. 1994 2 261 267.
39. Santeusanio F, D'Alfonso V, Iafrate E et al. Antibodies to cytokeratin 14 specifically identify oncocytes (Hürthle cells) in thyroid lesions and tumours. Appl. Immunohistochem. 1997 5 223 228.
40. Ni M, Lee AS. ER chaperones in mammalian development and human diseases. FEBS Lett. 2007 581 3641 3651.
41. Hebert DN, Molinari M. In and out of the ER: protein folding, quality control, degradation, and related human diseases. Physiol. Rev. 2007 87 1377 1408.
42. Appenzeller-Herzog C, Ellgaard L. The human PDI family: versatility packed into a single fold. Biochim. Biophys. Acta 2008 1783 535 548.
43. Hatahet F, Ruddock LW. Substrate recognition by the protein disulfide isomerases. FEBS J. 2007 274 5223 5234.
44. Maattanen P, Kozlov G, Gehring K, Thomas DY. ERp57 and PDI: multifunctional protein disulfide isomerases with similar domain architectures but differing substrate-partner associations. Biochem. Cell Biol. 2006 84 881 889.
45. Iida KI, Miyaishi O, Iwata Y, Kozaki KI, Matsuyama M, Saga S. Distinct distribution of protein disulfide isomerase family proteins in rat tissues. J. Histochem. Cytochem. 1996 44 751 759.
46. Baryshev M, Sargsyan E, Mkrtchian S. ERp29 is an essential endoplasmic reticulum factor regulating secretion of thyroglobulin. Biochem. Biophys. Res. Commun. 2006 340 617 624. (Pubitemid 43021791)
47. Sargsyan E, Baryshev M, Szekely L, Sharipo A, Mkrtchian S. Identification of ERp29, an endoplasmic reticulum lumenal protein, as a new member of the thyroglobulin folding complex. J. Biol. Chem. 2002 277 17009 17015.
48. Mezghrani A, Courageot J, Mani JC, Pugniere M, Bastiani P, Miquelis R. Protein-disulfide isomerase (PDI) in FRTL5 cells. pH-dependent thyroglobulin/PDI interactions determine a novel PDI function in the post-endoplasmic reticulum of thyrocytes. J. Biol. Chem. 2000 275 1920 1929.
49. Volante M, Collini P, Nikiforov YE et al. Poorly differentiated thyroid carcinoma: the Turin proposal for the use of uniform diagnostic criteria and an algorithmic diagnostic approach. Am. J. Surg. Pathol. 2007 31 1256 1264.
50. de Matos PS, Ferreira AP, de Oliveira Facuri F, Assumpcao LV, Metze K, Ward LS. Usefulness of HBME-1, cytokeratin 19 and galectin-3 immunostaining in the diagnosis of thyroid malignancy. Histopathology 2005 47 391 401.
51. Casey MB, Lohse CM, Lloyd RV. Distinction between papillary thyroid hyperplasia and papillary thyroid carcinoma by immunohistochemical staining for cytokeratin 19, galectin-3, and HBME-1. Endocr. Pathol. 2003 14 55 60.
52. Nasr MR, Mukhopadhyay S, Zhang S, Katzenstein AL. Immunohistochemical markers in diagnosis of papillary thyroid carcinoma: utility of HBME1 combined with CK19 immunostaining. Mod. Pathol. 2006 19 1631 1637.
53. Weibel ER. Stereological principles for morphometry in electron microscopic cytology. Int. Rev. Cytol. 1969 26 235 302.
54. Collett D. Modelling survival data in medical research, 2nd edn. Boca Raton, FL : Chapman & Hall/CRC, 2003 391.
55. Harrell F, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat. Med. 1996 15 361 387.
56. Tremblay G, Pearse AG. Histochemistry of oxidative enzyme systems in the human thyroid, with special reference to Askanazy cells. J. Pathol. Bacteriol. 1960 80 353 358.
57. Hedinger C, Williams ED, Sobin LH. Histological typing of thyroid tumours, 2nd edn. Berlin : Springer, 1988.
58. Toivola DM, Tao GZ, Habtezion A, Liao J, Omary MB. Cellular integrity plus: organelle-related and protein-targeting functions of intermediate filaments. Trends Cell Biol. 2005 15 608 617.
59. Boldogh IR, Pon LA. Mitochondria on the move. Trends Cell Biol. 2007 17 502 510.
60. Shintaku M, Honda T. Identification of oncocytic lesions of salivary glands by anti-mitochondrial immunohistochemistry. Histopathology 1997 31 408 411.
61. Tasca C, Negoescu I, Stefaneanu L, Ionescu N. Electronoptical aspects of the thyroid cold nodule. Endocrinologie 1979 17 265 269.
62. Stefaneanu L, Tasca C. An electron-microscopic study of human thyroid cancer. Endocrinologie 1979 17 233 239.
63. Valenta LJ, Michel-Bechet M. Ultrastructure and biochemistry of thyroid carcinoma. Cancer 1977 40 284 300.
64. Johannessen JV, Sobrinho-Simoes M, Finseth I, Pilstrom L. Ultrastructural morphometry of thyroid neoplasms. Am. J. Clin. Pathol. 1983 79 166 171.
65. Walter L, Hajnoczky G. Mitochondria and endoplasmic reticulum: the lethal interorganelle cross-talk. J. Bioenerg. Biomembr. 2005 37 191 206.
66. Yasuhara S, Asai A, Sahani ND, Martyn JA. Mitochondria, endoplasmic reticulum, and alternative pathways of cell death in critical illness. Crit. Care Med. 2007 35 S488 S495.
67. Graier WF, Frieden M, Malli R. Mitochondria and Ca(2+) signaling: old guests, new functions. Pflugers Arch. 2007 455 375 396.
68. Armstrong JS. The role of the mitochondrial permeability transition in cell death. Mitochondrion 2006 6 225 234.
69. Armstrong JS. Mitochondrial membrane permeabilization: the sine qua non for cell death. BioEssays 2006 28 253 260.
70. Hajnoczky G, Csordas G, Das S et al. Mitochondrial calcium signalling and cell death: approaches for assessing the role of mitochondrial Ca2+ uptake in apoptosis. Cell Calcium 2006 40 553 560.
71. Pizzo P, Pozzan T. Mitochondria-endoplasmic reticulum choreography: structure and signaling dynamics. Trends Cell Biol. 2007 17 511 517.
72. Lao Y, Chang DC. Study of the functional role of Bcl-2 family proteins in regulating Ca(2+) signals in apoptotic cells. Biochem. Soc. Trans. 2007 35 1038 1039.
73. Muller-Hocker J. Oncocytic metaplasia/neoplasia - morphology, biochemistry, molecular genetics. Pathologe 1998 19 104 114.
74. Valenta LJ, Michel-Bechet M, Warshaw JB, Maloof F. Human thyroid tumors composed of mitochondrion-rich cells: electron microscopic and biochemical findings. J. Clin. Endocrinol. Metab. 1974 39 719 733.
75. Belchetz G, Cheung CC, Freeman J, Rosen IB, Witterick IJ, Asa SL. Hürthle cell tumors: using molecular techniques to define a novel classification system. Arch. Otolaryngol. Head Neck Surg. 2002 128 237 240.
76. Stojadinovic A, Hoos A, Ghossein RA et al. Hürthle cell carcinoma: a 60-year experience. Ann. Surg. Oncol. 2002 9 197 203.